A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引:1
作者
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
关键词
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I
10.1016/j.jtho.2017.09.301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
JCES 01.12
引用
收藏
页码:S1735 / S1735
页数:1
相关论文
共 50 条
  • [41] MODEL PHARMACOECONOMIC STUDY ON IRESSA® (GEFITINIB) AS A FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AT STAGE IIIB/IV IN EGFR MUTATION POSITIVE BULGARIAN PATIENTS
    Getov, Ilko
    Grigorov, Evgeni
    Naseva, Emilia
    Kojnov, Krassimir
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2013, 27 (01) : 3586 - 3594
  • [42] A phase II study of osimertinib in patients with NSCLC harboring EGFR exon 20 insertion: A multicenter trial of the Korean Cancer Study Group (LU17-19)2 2
    Kim, Yu Jung
    Kim, Soyeon
    Kim, Tae Min
    Suh, Koung Jin
    Kim, Miso
    Kim, Se Hyun
    Keam, Bhumsuk
    Kim, Dong-Wan
    Lee, Jong Seok
    Heo, Dae Seog
    LUNG CANCER, 2024, 194
  • [43] Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study
    Kenmotsu, Hirotsugu
    Wakuda, Kazushige
    Mori, Keita
    Kato, Terufumi
    Sugawara, Shunichi
    Kirita, Keisuke
    Yoneshima, Yasuto
    Azuma, Koichi
    Nishino, Kazumi
    Teraoka, Shunsuke
    Shukuya, Takehito
    Masuda, Ken
    Hayashi, Hidetoshi
    Toyozawa, Ryo
    Miura, Satoru
    Fujimoto, Daichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Takahashi, Toshiaki
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : 1098 - 1108
  • [44] BE-POSITIVE: GEFITINIB IN FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS HARBORING ACTIVATING EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS. A COMBINED RETROSPECTIVE AND PROSPECTIVE ANALYSIS FROM ITALIAN PATIENTS.
    Novello, Silvia
    Alessandro, Follador
    Morabito, Alessandro
    Levra, Matteo Giaj
    Menis, Jessica
    Bria, Emilio
    Martelli, Olga
    Galetta, Domenico
    Spitaleri, Gianluca
    Caffo, Orazio
    Tiseo, Marcello
    Cecere, Fabiana
    Rijavec, Erika
    Zilembo, Nicoletta
    Banna, Giuseppe
    Rossi, Antonio
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S900 - S901
  • [45] Randomized Phase II Study of Cetuximab and Bevacizumab in Combination with Two Regimens of Paclitaxel and Carboplatin in Chemonaive Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer
    Bonomi, Philip D.
    Mace, Joseph
    Mandanas, Romeo A.
    Min, Myo
    Olsen, Mark
    Youssoufian, Hagop
    Katz, Terry L.
    Sheth, Grishma
    Lee, Hyun Jung
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (03) : 338 - 345
  • [46] Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial
    Riudavets, Mariona
    Naigeon, Marie
    Texier, Matthieu
    Dorta, Miriam
    Barlesi, Fabrice
    Mazieres, Julien
    Varga, Andrea
    Cassard, Lydie
    Boselli, Lisa
    Grivel, Jonathan
    NgoCamus, Maud
    Lacroix, Ludovic
    Mezquita, Laura
    Besse, Benjamin
    Chaput, Nathalie
    Planchard, David
    LUNG CANCER, 2022, 166 : 255 - 264
  • [47] A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer
    Suzuki, R.
    Hasegawa, Y.
    Baba, K.
    Saka, H.
    Saito, H.
    Taniguchi, H.
    Yamamoto, M.
    Matsumoto, S.
    Kato, K.
    Oishi, T.
    Imaizumi, K.
    Shimokata, K.
    BRITISH JOURNAL OF CANCER, 2006, 94 (11) : 1599 - 1603
  • [48] Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403
    Oda, Naohiro
    Ichihara, Eiki
    Hotta, Katsuyuki
    Ninomiya, Kiichiro
    Ninomiya, Takashi
    Kubo, Toshio
    Minami, Daisuke
    Murakami, Toshi
    Yokoyama, Toshihide
    Harada, Daijiro
    Kuyama, Shoichi
    Ichikawa, Hirohisa
    Inoue, Koji
    Kishino, Daizo
    Inoue, Masaaki
    Takigawa, Nagio
    Shibayama, Takuo
    Harita, Shingo
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    CLINICAL LUNG CANCER, 2017, 18 (02) : 241 - 244
  • [49] Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
    Cufer, Tania
    Vrdoljak, Eduard
    Gaafar, Rabab
    Erensoy, Inci
    Pemberton, Kristine
    ANTI-CANCER DRUGS, 2006, 17 (04) : 401 - 409
  • [50] Efficacy and Safety of Gefitinib as Third-line Treatment in NSCLC Patients With Activating EGFR Mutations Treated With First-line Gefitinib Followed by Second-line Chemotherapy A Single-Arm, Prospective, Multicenter Phase II Study (RE-CHALLENGE, CTONG1304)
    Song, Yong
    Wu, Yi-Long
    Cao, Le-Jie
    Chen, Jian-Hua
    Ma, Zhi-Yong
    Cui, Jiu-Wei
    Wang, Jie
    Liu, Hong-Bing
    Ding, Jing-Yan
    Hu, Min
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (05): : 432 - 439